10.32
0.49%
0.05
Dopo l'orario di chiusura:
10.31
-0.010
-0.10%
Precedente Chiudi:
$10.27
Aprire:
$10.34
Volume 24 ore:
1.04M
Relative Volume:
0.80
Capitalizzazione di mercato:
$559.18M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.6992
EPS:
-14.76
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
+24.79%
1M Prestazione:
+11.09%
6M Prestazione:
+36.87%
1 anno Prestazione:
+337.29%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Confronta EBS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.32 | 559.18M | 1.02B | -757.20M | -257.90M | -14.76 |
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-30 | Iniziato | H.C. Wainwright | Buy |
2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
2023-11-20 | Ripresa | JP Morgan | Underweight |
2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
2021-05-05 | Downgrade | Argus | Buy → Hold |
2021-04-07 | Iniziato | The Benchmark Company | Buy |
2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-09-14 | Ripresa | JP Morgan | Neutral |
2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
2019-09-12 | Iniziato | Guggenheim | Buy |
2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
2018-06-13 | Iniziato | Argus | Buy |
2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
2018-01-24 | Iniziato | Goldman | Neutral |
2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
2016-06-28 | Reiterato | Singular Research | Buy |
2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
2016-03-28 | Iniziato | Singular Research | Buy |
2016-02-19 | Iniziato | Wells Fargo | Outperform |
2014-05-15 | Iniziato | Summer Street Research | Buy |
2011-05-31 | Reiterato | WBB Securities | Strong Buy |
2011-01-10 | Reiterato | Wedbush | Outperform |
2010-11-05 | Reiterato | Wedbush | Outperform |
2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN
Emergent BioSolutions stock leverages NARCAN and vaccine sales for long-term potential - Investing.com Canada
Emergent BioSolutions (EBS) Stock Surge Explained - GuruFocus.com
Why Emergent BioSolutions Stock Blasted Higher Today - MSN
Emergent BioSolutions (NYSE:EBS) Stock Price Up 11.9%What's Next? - MarketBeat
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Emergent BioSolutions (NYSE:EBS) Coverage Initiated at HC Wainwright - MarketBeat
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
State Street Corp Has $15.96 Million Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Kenvue to Replace Advance Auto Parts in S&P 500; Emergent BioSolutions to be Removed From S&P SmallCap 600 - Marketscreener.com
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine - MSN
Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to Hold - MarketBeat
Emergent BioSolutions receives $50 million contract option from BARDA - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Emergent BioSolutions Inc. Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - Marketscreener.com
Emergent secures $50 million BARDA anthrax vaccine contract By Investing.com - Investing.com Australia
Emergent BioSolutions Receives $50 Million Contract Option from BARDA - citybiz
Emergent secures $50 million BARDA anthrax vaccine contract - Investing.com
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Lands $50M BARDA Contract for FDA-Approved Anthrax Vaccine CYFENDUS - StockTitan
Know Future Outlook of Vaccine Conjugates Market: Key Players Sanofi Pasteur, Emergent BioSolutions - openPR
Oak Hill Advisors LP Invests $9.30 Million in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
War On Drugs 'Has Failed, Completely And Utterly': UN High Commissioner Urges Evidence-Based Solutions - Benzinga
Shigella Infections Market: Projected to Expand Significantly - openPR
Jacobs Levy Equity Management Inc. Invests $1.55 Million in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Emergent to sell Baltimore-Camden production site for $30M - MSN
Point72 Asia Singapore Pte. Ltd. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) lost 9.5% last week but have reaped the benefits of longer-term growth - Simply Wall St
Emergent BioSolutions (EBS) Shares Fall Amidst Institutional Sel - GuruFocus.com
Why Emergent BioSciences Stock Plummeted Today - Yahoo! Voices
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook (SIGA) - Seeking Alpha
Emergent BioSolutions (FRA:ER4) Total Liabilities : €873 Mil (As of Sep. 2024) - GuruFocus.com
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Benzinga
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN
Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK
Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com
Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):